



## NaBC1 (T-20): sc-55141

### BACKGROUND

NaBC1 (novel amplified in breast cancer 1) is a protein found amplified in most breast carcinoma forms. It is expressed primarily as a cytoplasmic, detergent-stable homodimer that has a tendency to interact with DYNLL1 (PIN) and DYNLL2. Breast tumor lines that exhibit 20q13.2 gene amplification express much higher levels of the protein as compared to the levels found in other breast cancer lines that do not overexpress the NaBC1 mRNA. However, this upregulation does not affect growth rate or anchoring abilities of a cell, indicating the oncogenic properties of NaBC1 differ from that of other oncogenes.

### REFERENCES

- Collins, C., et al. 1998. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. *Proc. Natl. Acad. Sci. USA* 95: 8703-8708.
- Correa, R.G., et al. 2000. NaBC1 (BCAS1): alternative splicing and down-regulation in colorectal tumors. *Genomics* 65: 299-302.
- Ishimoto, T., et al. 2002. Cloning and characterization of a novel synaptosome-enriched mRNA that encodes 31 kDa protein. *Biochim. Biophys. Acta* 1579: 189-195.
- Zhao, C., et al. 2003. Elevated expression levels of NCoA-3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. *Cancer* 98: 18-23.
- Beardsley, D.I., et al. 2003. Characterization of the novel amplified in breast cancer 1 (NABC1) gene product. *Exp. Cell Res.* 290: 402-413.
- Aust, D.E., et al. 2004. Prognostic relevance of 20q13 gains in sporadic colorectal cancers: a FISH analysis. *Scand. J. Gastroenterol.* 39: 766-772.
- van Dekken, H., et al. 2006. Genomic array and expression analysis of frequent high-level amplifications in adenocarcinomas of the gastroesophageal junction. *Cancer Genet. Cytogenet.* 166: 157-162.
- Loukopoulos, P., et al. 2007. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. *Cancer Sci.* 98: 392-400.
- Johnson, N., et al. 2007. A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. *Breast Cancer Res. Treat.* E-published ahead of print.

### CHROMOSOMAL LOCATION

Genetic locus: Bcas1 (mouse) mapping to 2 H3.

### SOURCE

NaBC1 (T-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of NaBC1 of mouse origin.

### STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-55141 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

### APPLICATIONS

NaBC1 (T-20) is recommended for detection of NaBC1 of mouse and rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for NaBC1 siRNA (m): sc-62658.

Molecular Weight of NaBC1 monomer: 60 kDa.

Molecular Weight of NaBC1 dimer: 120 kDa.

### RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

### RESEARCH USE

For research use only, not for use in diagnostic procedures.

### PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.